Complementary use of drug and small-molecule screen with CRISPR/Cas9 screen to identify factors that enhance the cytotoxicity of CAR T cells. This approach can provide new ways to identify mediators of CAR and tumor activity that are relevant across tumor types and CAR constructs for further investigation.